Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Knoll Aktiengesellschaft

Basf Aktiengesellschaft

Abbvie Inc.

Abbvie Bahamas Limited

Makoto, Aoyama

Paul Rafferty

Lee Daniel Arnold

David J Calderwood

Gavin C Hirst

Kurt Ritter

Michael Michaelides

James Edward Jeffery

Carol K Wada

Steven K Davidsen

Michael L Curtin

Michael M Friedman

Robin R Frey

Howard Robin Heyman

Neil Wishart

Rainer Munschauer

Kelly Mullen

Andrew Burchat

David N Johnston

Peter Hrnciar

Heather M Davis

Anna M Ericsson

Stevan Wakefield Djuric

Alan Frank Gasiecki

Richard W Dixon

James H Holms

Teresa Barlozzari

Irini Akritopoulou-Zanze

Douglas H Steinman

Henry Q Zhang

Michael R Michaelides

David John Calderwood

Adrian John Fisher

Melanie A Muckey

Patrick Betschmann

Helen L Twigger

Gerald Bernard Tometzki

Kevin James Doyle

Colin Gerhart Pryce Jones

Robert W Steele

Colin Gerhart Jones

Isabel Fernandez

David J Wilkins

Allyson Turner

Michael Hockley

Zhiren Xia

Hormoz Mazdiyasni

Makoto Takeshita

Marina Moran Moset

Jose Maria Castellano Berlanga

Vijaya J Gracias

Jürgen Dinges

Kimba Lee Fischer

Yajun Xu

Nobuhiko Iwasaki

Bojuan B Deng

Gerald B Tometzki

Stephen St Gallay

Beatriz Gonzalez Pascual

Jose L Ortego Martinez

Maria J Perez De Vega

Nobuo Ogawa

Howard R Heyman

Andrew F Burchat

Lee D Arnold

Aoyama Makoto

Kimba Fischer

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thienopyridine and furopyridine kinase inhibitors

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

4-aminopyrrolopyrimidines as kinase inhibitors

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Tricyclic pyrazole kinase inhibitors

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R, R, and Rare defined as described herein.

Pyrazolopyrimidines as therapeutic agents

The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.

Kinase inhibitors as therapeutic agents

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

2-pyrazolin-5-ones

 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

Benzothiazinone and benzoxazinone compounds

The present invention is directed to pyrazolopyrimidine derivatives of formula (I)wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Pyrrolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Chemical compounds that are derivatives of indeno&lsqb;1,2-c&rsqb;pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell proliferation is a factor. Compounds of this invention also inhibit the induction of vascular hyperpermeability and the associated formation of edema, ascites, and exudates.

Indeno&lsqb;1,2-C&rsqb;pyrazole derivatives for inhibiting tyrosine kinase activity

This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.

Tricyclic pyrazole derivatives

Imidazole derivatives for blocking the release of arachidonic acid from phospholipids

Growing community of inventors

Westborough, MA, United States of America

Paul Rafferty